Vertex Pharmaceuticals Inc (VRTX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$491.00
Buy
$502.00
$2.29 (+0.46%)
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
Prices updated at 03 May 2025, 00:58 BST
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Jeffrey M Leiden, PhD
CEO
Dr. Reshma Kewalramani, M.D.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
6,100
Head office
50 Northern Avenue
Boston
United States
02210
Key personnel
| Owner name | Salary | Bonus | All other compensation | Total compensation | Restricted stock award |
|---|---|---|---|---|---|
Mr. Charles F. Wagner, Jr Executive Vice President and Chief Financial Officer | 0.88m | - | - | 8.00m | - |
Mr. Stuart A. Arbuckle Executive Vice President and Chief Operating Officer | 0.94m | - | - | 9.38m | - |
Mr. Duncan J. McKechnie Senior Vice President and Head, North America Commercial Team | - | - | - | - | - |
Mr. Amit K. Sachdev, J.D. Executive Vice President and Chief Patient and External Affairs Officer | - | - | - | - | - |
Mr. Bruce I. Sachs Lead Independent Director | 0.18m | - | - | 0.60m | - |
Mr. Lloyd A. Carney Independent Director | 0.14m | - | - | 0.56m | - |
Dr. Jeffrey M Leiden, PhD Executive Chairman of the Board | - | - | - | - | - |
Dr. Alan M. Garber, M.D.,PhD Independent Director | 0.12m | - | - | 0.52m | - |
Mr. Suketu Upadhyay Independent Director | 0.14m | - | - | 0.56m | - |
Mr. Michel Lagarde Independent Director | 0.11m | - | - | 0.54m | - |
Dr. David Altshuler, M.D.,PhD Executive Vice President and Chief Scientific Officer | 0.88m | - | - | 7.64m | - |
Dr. Sangeeta N. Bhatia, PhD Independent Director | 0.14m | - | - | 0.55m | - |
Ms. Diana L. McKenzie Independent Director | 0.13m | - | - | 0.55m | - |
Dr. Reshma Kewalramani, M.D. Director, President and Chief Executive Officer | 1.54m | - | - | 21.54m | - |
Mr. Jonathan Biller Executive Vice President and Chief Legal Officer | - | - | - | - | - |
Dr. Jennifer Schneider, M.D. Independent Director | 0.07m | - | - | 0.50m | - |
Dr. Ourania Tatsis, PhD Executive Vice President and Chief Regulatory and Quality Officer | - | - | - | - | - |
Dr. Carmen Bozic Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer | - | - | - | - | - |
Ms. Nancy A. Thornberry Independent Director | 0.11m | - | - | 0.52m | - |
Ms. Kristen C. Ambrose Senior Vice President and Chief Accounting Officer | - | - | - | - | - |
Dr. E Morrow Atkinson, III, PhD Executive Vice President, Chief Technical Operations Officer and Head, Biopharmaceutical Science and Manufacturing Operations | - | - | - | - | - |
Dr. Nia Tatsis Executive Vice President and Chief Regulatory and Quality Officer | 0.69m | - | - | 7.33m | - |
Top 5 shareholders
| Owner name | No. of shares | Share as % of port. | Last change | Portfolio % change | Date of portfolio | % Total assets |
|---|---|---|---|---|---|---|
| Capital Research and Management Company | 42,414,577 | 47.84954 | 4123326 | - | 30 Apr 2025 | 16.52 |
| Capital Group | 29,255,419 | 20.20573 | 3734229 | - | 30 Apr 2025 | 11.39 |
| Capital World Investors | 28,325,695 | 1.73168 | 1514993 | 5.650702 | 30 Apr 2025 | 11.03 |
| Vanguard Group Inc | 23,258,288 | 0.16314 | 98654 | 0.425974 | 30 Apr 2025 | 9.06 |
| BlackRock Inc | 21,825,470 | 0.17785 | 37924 | 0.174063 | 30 Apr 2025 | 8.50 |
Director dealings
| Date | Action | Name | Price | Value | No. of shares | Holding (%) | Additional info |
|---|---|---|---|---|---|---|---|
| 15 Nov 2024 | - | Dr. David Altshuler | 478.56 | 7,178 | 25,813 | - | - |
| 11 Nov 2024 | - | Mr. Charles F. Wagner, Jr | 518.27 | 1,554,810 | 44,137 | - | - |
| 08 Nov 2024 | - | Dr. Reshma Kewalramani, M.D. | 515.00 | 7,826,970 | 75,772 | - | - |
| 15 Oct 2024 | - | Mr. Bruce I. Sachs | 484.39 | 43,595 | 15,033 | - | - |
| 01 Oct 2024 | - | Mr. Jonathan Biller | 466.84 | 294,109 | 17,650 | - | - |
| 02 Oct 2024 | - | Mr. Jonathan Biller | 461.66 | 461,198 | 16,651 | - | - |
| 30 Aug 2024 | - | Dr. Jeffrey M Leiden, PhD | 499.00 | 1,888,216 | 9,994 | - | - |
| 30 Aug 2024 | - | Dr. Sangeeta N. Bhatia, PhD | 500.00 | 323,000 | 4,435 | - | - |
| 30 Aug 2024 | - | Dr. Sangeeta N. Bhatia, PhD | - | - | - | - | - |
| 30 Aug 2024 | - | Dr. Sangeeta N. Bhatia, PhD | 152.74 | 98,670 | 5,081 | - | - |
| 08 Aug 2024 | - | Dr. Sangeeta N. Bhatia, PhD | 152.74 | 197,340 | 5,727 | - | - |
| 08 Aug 2024 | - | Dr. Sangeeta N. Bhatia, PhD | - | - | 646 | - | - |
| 08 Aug 2024 | - | Dr. Sangeeta N. Bhatia, PhD | 466.29 | 602,447 | 4,435 | - | - |
| 07 Aug 2024 | - | Ms. Carmen Bozic | 476.75 | 1,086,990 | 23,259 | - | - |
| 01 Aug 2024 | - | Mr. Bruce I. Sachs | 125.71 | 665,634 | 45,295 | - | - |
| 01 Aug 2024 | - | Mr. Bruce I. Sachs | - | - | - | - | - |
| 01 Aug 2024 | - | Mr. Bruce I. Sachs | 508.00 | 2,689,860 | 40,000 | - | - |
| 30 Jul 2024 | - | Dr. Reshma Kewalramani, M.D. | 505.00 | 7,677,010 | 90,970 | - | - |
| 24 Jul 2024 | - | Ms. Carmen Bozic | 488.46 | 1,113,689 | 25,539 | - | - |
| 22 Jul 2024 | - | Dr. Reshma Kewalramani, M.D. | 497.00 | 7,555,394 | 106,172 | - | - |
Please note that past performance is not a reliable indicator of future returns.
